What happened
- The FDA approved Lembaz (adrabetadex) on 17 Nov 2026 to reduce the risk of death in people with Niemann-Pick disease type C whose neurological symptoms began before age 6.
- Across three studies and an expanded access program, 36 treated patients had a 55% lower risk of death than a matched external control group. Median survival was 8.5 years versus 4.9 years.
- It is given into the spinal canal every two weeks by a trained provider.
What we don't know yet
- The comparison was with an external (historical) control group, not a randomized one.
- Niemann-Pick type C affects about 1 in 150,000 people, so the evidence base is small.
Primary sources
- FDA press announcement, 17 Nov 2026Regulator decision
Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.